Elite Pharmaceuticals Inc (ELTP) KPIs and segments
Close on Oct 19, 2026Market cap $281.77MP/E 5.0Yield –
KPIs & segments
Operating metrics and segments that drive Elite Pharmaceuticals's business
Elite Pharmaceuticals's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
Elite Pharmaceuticals's fiscal year ends March 31 — Q1 FY27 = CQ2 2026 (calendar quarter).
| Add to chart | Metric | Q1 FY27 CQ2 2026 | Q4 FY26 CQ1 2026 | Q3 FY26 CQ4 2025 | Q2 FY26 CQ3 2025 | Q1 FY26 CQ2 2025 | Q4 FY25 CQ1 2025 | Q3 FY25 CQ4 2024 | Q2 FY25 CQ3 2024 | Q1 FY25 CQ2 2024 | Q4 FY24 CQ1 2024 | Q3 FY24 CQ4 2023 | Q2 FY24 CQ3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbreviated New Drug Applications($M)2 | 40.2 | 32.0 | 14.4 | 18.9 | 18.8 | 17.9 | 15.5 | 14.2 | |||||
Manufacturing($M) | 39.8 | 31.6 | 13.7 | 18.2 | 18.4 | 17.9 | 14.8 | 13.5 | |||||
Licensing($M) | 0.43 | 0.42 | 0.63 | 0.66 | 0.36 | 0.04 | 0.75 | 0.65 | |||||
New Drug Applications($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Manufacturing($M) | 40.5 | 31.4 | 36.2 | 39.8 | 31.6 | 13.7 | 18.2 | 18.4 | 17.9 | 14.8 | 13.5 | ||
ANDA Revenue($M) | 32.1 | 39.8 | |||||||||||
Scheduled Products Manufacturing Fees($M) | 27.8 | 38.9 | |||||||||||
Direct Sales to Wholesalers($M) | 16.4 | 19.0 | |||||||||||
Indirect Sales to Wholesalers($M) | 15.7 | 20.7 | |||||||||||
Unscheduled Products Manufacturing Fees($M) | 4.32 | 0.86 | |||||||||||
Unscheduled Products Licensing Fees($M) | 0.43 | ||||||||||||
Licensing($M) | 0.22 | 0.30 | 0.21 | 0.13 | 0.43 | 0.42 | 0.63 | 0.66 | 0.36 | 0.04 | 0.75 | 0.65 | |
Scheduled Products Licensing Fees($M) | 0.22 | ||||||||||||
Business Segment($M) | 11.9 | 12.7 | 25.6 | 15.3 | 4.33 | 6.23 | 6.31 | 6.40 | 5.64 | 3.83 | |||
Abbreviated New Drug Applications($M) | 11.9 | 12.7 | 25.6 | 15.3 | 4.33 | 6.23 | 6.31 | 6.40 | 5.64 | 3.83 | |||
Earlier reporting (last reported 2023)1 | |||||||||||||
15 metrics have no data in the last 12 quarters — .
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
Data updated 2026-08-13.
See a number that looks wrong?